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1. INTRODUCTION 
While in the new immunosuppression era, graft damage caused 
by acute cellular rejection has almost disappeared, due to the 
increasing number of human leukocyte antigen (HLA)-
mismatched transplantations and sensitization of the recipients 
at B-cell level, antibody-mediated rejection (AMR) still 
remains a problem. Therefore, prevention of AMR became an 
important issue in the field of kidney transplantation. 
In the pathogenesis of AMR complement activation caused by 
preformed donor-specific HLA immunoglobulin (Ig) G 
antibodies (DSA) play a critical role. To protect graft function, 
a combination of different diagnostic measures, such as HLA-
typing, crossmatch (XM) and antibody screening is needed. 
XM techniques are assays to identify the presence of 
preformed DSA against donor HLA class I and II antigens in 
the serum of recipients before transplantation on the kidney 
transplant waiting list. For crossmatching, the recipient’s serum 
and donor lymphocytes have to be available. 
To avoid a positive XM in the transplant centers and thus 
prevent AMR, kidney transplant recipients are screened 
periodically for the presence of HLA antibodies before 
transplantation to define the „unacceptable HLA antigen 
mismatches”. For the detection of DSA, serum of the recipient 
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has to be available, but instead of the lymphocytes of potential 
donor, a panel of HLA-typed lymphocytes from healthy blood 
donors, their solubilized HLA antigens or artificially produced 
recombinant HLA molecule panels are utilized. 
Different assays for identification of HLA antibodies vary in 
the type of target, format, sensitivity and specificity. Assay 
targets can either be cells tested for example in cytotoxicity 
assay, such as complement-dependent cytotoxicity assay 
(CDC) or soluble antigens tested in solid-phase immunoassays 
such as enzyme-linked immunosorbent assay (ELISA) and 
Luminex single antigen bead (SAB) technique. With increasing 
sensitivity of the diagnostic assays, weak DSA can be detected 
appropriately in serum of recipients on the kidney transplant 
waiting list. While CDC assay can detect from very high to 
high or moderate DSA levels, ELISA assay is more sensitive to 
determine moderate or low antibody reactivity in the 
recipient’s serum. Nowadays, Luminex SAB is the only 
methodology with its high sensitivity, which can detect low 
titer DSA with high accuracy.  
Currently it is a matter of debate, which antibody test at what 
sensitivity should be used in the pretransplant evaluation of 
alloantibodies before kidney transplantation. 
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2. THE AIMS OF THE THESIS 
False positive results as well as low sensitivity can create 
difficulties in the correct assessment of the patient’s HLA 
antibody status on the kidney transplant waiting list. We 
analyzed the advantages and the problems associated with two 
recently introduced HLA antibody detection methods. 
In the first study we investigated the potential superiority of the 
commercially available AbCross
®
 ELISA XM over the B-cell 
CDC XM (BXM) in predicting graft loss. Because there is 
debate about the sensitivity and clinical relevance of the BXM 
in renal transplantation, we analyzed, whether with the new 
AbCross
®
 technique the disadvantages of the BXM, such as the 
detection of unspecific reactions or autoantibodies, can be 
eliminated.  
In the second study, to estimate the impact of the problem of 
potentially “false positive” results detected with the highly 
sensitive Luminex SAB technique on the sensitization status of 
patients on the kidney transplant waiting list, we investigated 
the prevalence of HLA antibodies in waiting list patients of the 
Heidelberg transplant center using three different assays, 
namely CDC T-cell screening, AbScreen
®
 ELISA screening, 
and SAB in parallel. A high prevalence of HLA antibody 
reactivity with a given assay in patients without any history of 
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immunization would indicate that this particular assay 
generates false positive results. We also examined in detail the 
HLA specificity and strength of the false positive reactions. 
Such information could be useful in the daily routine, when 
SAB results are evaluated in the individual patients. 
 
2.1  Comparison of the clinical relevance of ELISA and 
B-cell CDC crossmatch before kidney 
transplantation 
The following questions were addressed: 
a.  What is the rate of 2-year graft loss after kidney 
transplantation in AbCross
®
 ELISA XM-positive and 
AbCross
®
 ELISA XM-negative patients? 
b.  What is the rate of 2-year graft loss after kidney 
transplantation in BXM-positive patients compared to 
BXM-negative patients? 
c.  Is the impact of positivity in AbCross
®
 ELISA XM on 
graft survival supported by AbScreen
®
 ELISA screening 
results? 
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d.  Is there a relationship between kidney graft survival and 
BXM and AbCross
®
 ELISA XM or AbScreen
®
 ELISA 
screening results? 
 
2.2  Evaluation of the influence of the recently 
introduced Luminex SAB on the sensitization status 
of patients on the kidney transplant waiting list  
In this context, the following questions were addressed: 
a. What is the prevalence of the positive patients on the 
kidney transplant waiting list in the SAB technique 
compared to the less sensitive ELISA and CDC methods? 
b. What is the prevalence of HLA antibody-positive patients 
without any immunization history? 
c. Which mean fluorescence intensity (MFI) values have 
patients without any history of immunization? 
d. Whether the problem of false positive results could be 
solved by increasing the cutoff values? 
e. What is the prevalence of SAB-positive patients according 
to reaction with the percentage of beads? 
f. Which HLA allele specificities react positive in SAB in 
patients without history of immunization? 
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g. Whether other methods, such as another vendor or another 
test principle, can solve the problem of false positive 
results? 
 
3.  PATIENTS AND METHODS 
3.1   Patients 
In the first study in which the potential superiority of the 
ELISA XM over the BXM before kidney transplantation 
was evaluated, pretransplant sera of 271 living or deceased 
donor kidney transplant recipients who were transplanted at the 
Heidelberg transplant center between 1998 and 2010 and on 
whom frozen donor cell material was available were tested in 
the AbScreen
®
 ELISA screening assay for the presence of 
HLA antibodies and in BXM and AbCross
®
 ELISA XM assays 
for antibody reactivity against donor B-cells or donor HLA 
class I and II antigens, respectively. 
In the second study in which the influence of the Luminex 
SAB test on the sensitization status of patients on the waiting 
list was evaluated in parallel with the ELISA and CDC 
screening methods, pretransplant sera of 534 patients on the 
Heidelberg kidney transplant waiting list were additionally 
analyzed using the SAB assay. 
7 
 
3.2  Methods 
3.2.1  Study 1: Comparison of the clinical relevance of 
ELISA and B-cell CDC crossmatch before kidney 
transplantation 
In the first study, for the CDC XM, the donor's separated B-
lymphocytes were used and the cytotoxicity effect was 
examined using a fluorescent microscope (Leica, Wetzlar, 
Germany). Cell death >20% was considered positive. 
In addition, sera were tested using the recently introduced 
AbCross
®
 ELISA XM (BioRad, Munich, Germany) assay, in 
which solubilized donor HLA molecules are used to detect 
DSA. AbCross
®
 ELISA XM is a commercially available solid 
phase XM technique with advantages over the standard BXM, 
such as higher reproducibility, objectivity, sensitivity and 
specificity for HLA antigens. The AbCross
®
 ELISA XM assay 
detects antibodies on the microtiter plate coated with 
monoclonal antibodies. The results were detected with 
photometric measurement in an ELISA reader and optical 
density (OD) greater than or equal to the double of the negative 
control were considered positive. 
The sera were also tested for the presence of IgG-anti-HLA 
class I and II alloantibodies using AbScreen
®
 ELISA (BioRad) 
kits, which use pooled HLA molecules on 96-well microtiter 
8 
 
plates for the detection of HLA antibodies. HLA antibodies of 
the recipient are determined on separate plates against pooled 
class I or class II HLA molecules. Based on previous clinical 
findings, an OD of ≥0.300 was used as cutoff for anti-HLA 
positivity. 
Two-year clinical follow-up data were collected and 
documented for 223 of 271 patients and statistical analysis was 
performed using the chi-square test. 
 
3.2.2  Study 2: Evaluation of the influence of the recently 
introduced Luminex SAB on the sensitization status 
of patients on the kidney transplant waiting list 
In the second study, the different antibody screening 
techniques were analyzed. At the Heidelberg transplant center, 
waiting list patients are routinely screened every three months 
for HLA antibodies employing ELISA and CDC. In addition, 
the 534 sera from the third quarter of 2010 were examined 
using the SAB method. 
Panel reactive antibody (PRA) against total lymphocytes 
(mainly T-cells) of a panel of 56 cell donors on frozen/thawed 
cell trays were determined using the CDC method in the 
absence of DTT 
(http://www.ctstransplant.org/public/reagents/serolCell.shtml). 
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Following standard procedure, the patient’s serum was 
incubated with lymphocytes, complement was added and the 
trays were read using a fluorescent microscope (Leica, Wetzlar, 
Germany). PRA of >5% was considered positive. 
Furthermore, all 534 sera were tested for the presence of HLA 
class I and II alloantibodies using AbScreen
®
 ELISA kits of 
BioRad (Munich, Germany), which as mentioned already 
above, utilize pooled HLA molecules attached to microtiter 
plates and enable the detection of HLA-A, -B, -C, -DR, and -
DQ antibodies of the IgG isotype. Based on previous clinical 
findings, an OD of ≥0.300 was used as cutoff for anti-HLA 
positivity in ELISA. In one patient who was negative with 
SAB but positive by ELISA AbScreen
®
, the ELISA-PRA assay 
(AbIdent
®
, BioRad, Munich, Germany) which utilizes cell 
lysates from single individuals instead of pooled lysates was 
used to confirm the absence of HLA antibodies. 
In addition, all sera were tested using the LABScreen
®
 
Luminex kits of One Lambda (Canoga Park CA, USA, 
LS1A04 Lot006 and LS2A01 Lot008), using SAB-coated 
beads that enable the identification of IgG antibody 
specificities against HLA-A, -B, -C, -DRB1/3/4/5, -DQA1, -
DQB1, -DPA1 and -DPB1. Because no standard cutoff for the 
SAB assay is recommended by the manufacturer, the value of 
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MFI ≥1,000, which has been commonly indicated in the 
literature, was used as a cutoff. 
Sera of 10 male waiting list patients without a history of 
immunization, who were positive in the LabScreen
®
 SAB test 
against HLA alleles that are rather common in the general 
population, were tested subsequently in the Lifecodes
®
 SAB 
(Gene-Probe Transplant Diagnostics, Lifecodes
®
 LSA, 
Stamford, CT) assay, in which positivity is defined by the 
software of the manufacturer when two of the three standard 
calculation values are over the predetermined cutoff. 
Furthermore, sera defined as positive by the LabScreen
®
 SAB 
test of 20 male waiting list patients without a history of 
immunization and 15 non-immunized male healthy blood 
donors with unknown previous LabScreen
®
 SAB results, were 
tested in the LabScreen
®
 PRA assay (One Lambda), which 
utilizes 55 beads coated with HLA antigens purified from 55 
different human cell lines (phenotype panel). The cutoff for 
positivity was set at 1,000 MFI. 
Clinical background data including transfusions, pregnancies 
and previous transplantations were requested from the patient’s 
clinical care facilities. Fisher’s exact test was used for 
statistical comparison. 
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4. RESULTS 
4.1  Comparison of the clinical relevance of ELISA and 
B-cell CDC crossmatch before kidney 
transplantation 
To our questions the following answers were found: 
a. The 2-year graft loss rate in 37 recipients positive for DSA 
in AbCross
®
 against donor HLA class I or II antigens was 
19%, which is significantly higher than the 8% rate in 186 
recipients who were negative for both HLA antibody 
classes in AbCross
®
 (P=0.043). 
b. Within 2 years after transplantation, the rate of graft loss in 
14 CDC BXM-positive patients was 7%, not higher than 
the 9% rate in 206 CDC BXM-negative patients (P=0.79). 
c. Corresponding with the AbCross® ELISA XM results, 48 
patients positive for HLA class I or II antibodies on ELISA 
screening had at 2 years a significantly poorer graft 
outcome than 174 recipients who were negative for HLA 
class I and II antibodies (graft loss rate, 21% vs. 6%; 
P=0.002). 
d. When CDC BXM was analyzed in combination with the 
AbCross
®
 ELISA XM, the rate of graft loss 2 years 
12 
 
posttransplantation in 34 BXM-negative but AbCross
®
-
positive patients was 21% compared with 7% in 172 
BXM- and AbCross
®
-negative patients (P=0.012), and 9% 
in 11 BXM-positive but AbCross
®
-negative patients 
(P=0.39). The low number of BXM-positive and 
AbCross
®
-positive patients did not allow a meaningful 
analysis (n=3; 2-year graft loss rate, 0%). When CDC 
BXM was analyzed in combination with ELISA screening, 
the rate of graft loss at 2 years after transplantation in 44 
BXM-negative but AbScreen
®
-positive patients was 21%, 
significantly higher than the 6% rate in 162 BXM-negative 
and AbScreen
®
-negative patients (P=0.002) and higher 
than the 0% rate in 9 BXM-positive but AbScreen
®
-
negative patients (P=0.14). 
 
4.2  Evaluation of the influence of the recently 
introduced Luminex SAB on the sensitization status 
of patients on the kidney transplant waiting list 
To our questions the following answers were found: 
a. When all 534 patients on the waiting list were analyzed, 
5% (n=28) were positive for HLA antibodies in CDC, 14% 
(n=73) in ELISA screening and 81% (n=435) in SAB. 
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b. Medical records and patient interviews indicated that 133 
of these patients (32%) had not been exposed to any 
immunizing event, such as blood transfusions, pregnancies 
or previous transplantations. Only one of the 133 patients 
(1%) was positive in the ELISA screening test for HLA 
class II, all were negative in ELISA for HLA class I, and 
two patients were positive in CDC (2%). In contrast to 
these CDC and ELISA results, as many as 77% (n=102) of 
the patients without a history of immunization were found 
to possess HLA antibodies using SAB. 
c. At a cutoff of 2,000 MFI, 50% of the non-immunized 
patients were HLA antibody positive, and at a cutoff of 
5,000 MFI 25% of these patients were positive, showing 
that “false positive” reactions in the SAB assay were not 
restricted to “weak” reactions. 
d. Some of these antibodies reacted quite strongly, with MFI 
values up to 14,440, so that raising the reactivity cutoff did 
not eliminate the problem associated with these false 
positive reactions. 
e. Sera of CDC- and ELISA-negative patients without a 
history of immunization showed a restricted SAB 
reactivity pattern and reacted in 86% of the cases with 
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≤5% of the SABs. In contrast, 94% of the ELISA- or 
CDC-positive patients showed positive reactions against 
>5% of the SABs. 
f. Some patients without a history of sensitization had 
antibodies with high MFI values against HLA specificities 
that are rather common in the general population, such as 
A*24:02 (prevalence in this series: 8.8%, maximum MFI: 
12,197), B*08:01 (7.8%, MFI: 9,862), B*44:02 (7.8%, 
MFI: 10,427) or C*05:01 (7.8%, MFI: 3,962) (8.7%, 
12.5%, 9.0%, 9.1% population prevalence, respectively). 
Similarly, among patients with antibodies against HLA 
class II, some had antibodies against beads carrying DQB 
alleles that are rather common, such as DQB1*03:01 
(prevalence in this series: 7.8%, MFI: 9,804), which occurs 
at a frequency of 18.5% in the general population. 
g. When the more common HLA specificities were analyzed, 
8 of the 10 patients did not show HLA antibody reactivity 
in the SAB assay of the second vendor whereas 2 of the 10 
did. When 1,000 MFI was used as cutoff for positivity, 6 
(30%) of the 20 non-immunized male waiting list patients 
who were positive in SAB testing were also positive in the 
LabScreen
®
 PRA test. None of the 15 healthy male blood 
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donors was positive in this test whereas 9 of them had 
been shown positive in the LabScreen
®
 SAB assay with 
reactivities ranging from 1,011 to 4,424 MFI against 21 
different HLA alleles, among them B*44:02 which occurs 
in more than 7% of Caucasians. 
 
5. CONCLUSIONS 
Our data indicate that the AbCross
®
 ELISA XM is superior to 
the BXM, most likely because it detects antibodies against 
donor HLA antigens at a higher sensitivity. 
Refusal of donor kidneys to recipients based on HLA antibody 
specificities detected “exclusively” in the SAB assay is not 
advisable. False SAB reactions can be unveiled by pretesting 
with additional antibody assays. 
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